NVAX:NASDAQ
Novavax Inc
12,58 US$
arrow_downward
-0,63%(-0,080) 1D
13 ოქტ, 13:15:45 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
12,44 US$
High
12,84 US$
Low
12,21 US$
Mkt. cap
2,08 მლრდ.
Avg. vol.
7,43 მლნ.
Volume
4,05 მლნ.
52-wk high
13,38 US$
52-wk low
6,20 US$
EPS
-1,52 US$
Beta
2,44
Shares outstanding
164,95 მლნ.
No. of employees
749
Open
12,44 US$
High
12,84 US$
Low
12,21 US$
Mkt. cap
2,08 მლრდ.
Avg. vol.
7,43 მლნ.
Volume
4,05 მლნ.
52-wk high
13,38 US$
52-wk low
6,20 US$
EPS
-1,52 US$
Beta
2,44
Shares outstanding
164,95 მლნ.
No. of employees
749
News stories
From web sources and news partners
Benzinga
·
1 დღის წინ
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Simply Wall Street
·
2 დღის წინ
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
Yahoo Finance
·
6 დღის წინ
Novavax, Moderna stocks fall after WHO calls plague risk 'low'
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOჯონ სი ჯეიკობს
Employees749
Founded1987
HeadquartersGaithersburg, მერილენდი, ამერიკის შეერთებული შტატები
Sector-
Websitenovavax.com